{'fraction_non_alphanumeric': 0.02771362586605081, 'fraction_numerical': 0.0, 'mean_word_length': 6.410256410256411, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Neuroprotective mechanisms of statins in neurodegenerative diseases

Statins can induce neuroprotective effects by various mechanisms, such as by lowering cholesterol levels; decreasing β-amyloid production, serum apolipoprotein E (APOE) levels, and anti-inflammatory responses; modifying cognition-related receptors, and augmenting endothelial nitric oxide synthase. The use of statins has been related to many neurodegenerative conditions, such as Alzheimer’s disease and Parkinson’s disease. In our previous review, we discussed the neuroprotective effects of statins by enhancing the levels of endothelial nitric oxide synthase, impairing β-amyloid production, reducing reactive oxygen species, and modulating cognition-related receptors. The present review discusses the recent finding that statins slow down the progression of these neurodegenerative diseases.